---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-000813"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T17:08:16.926703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports Q3 net loss of $2.85M; cash $17.5M; hires Lee Arnold as CSO

## Summary
- Net loss increased to ~$2.85M for quarter vs $2.53M year ago; operating expenses rose 12% to $2.85M.
- Cash balance ~$17.5M at Dec 31, 2022; raised $8.9M net via ATM equity offers in nine fiscal months.
- Hired Lee Arnold, PhD (inventor of Tarceva) as Chief Scientific Officer; contracted NAMSA for planned oncology Hemopurifier trial.
- COVID-19 ICU trial in India continues (one patient treated); preclinical mPox and Long COVID studies underway.
- No government contract revenue recorded; $574K deferred revenue expected after NCI closeout review.

## SEC filing metadata
- accession: 0001683168-23-000813
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/0001683168-23-000813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-000813
- JSON: https://secwatch.observer/filing/0001683168-23-000813.json
- Plain text: https://secwatch.observer/filing/0001683168-23-000813.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported third quarter ended December 31, 2022 results: net income approximately $2,850,000.
  - Period: third quarter ended December 31, 2022
  - Net income: approximately $2,850,000
  - Result: reported results
  source text: Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/0001683168-23-000813-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.